Lowering Drug Prices by Once Again Putting Americans First

This EO seeks to optimize Federal health care programs, intellectual property protections, and safety regulations to provide access to prescription drugs at lower costs. The EO directs various agency actions to achieve this goal.

• HHS

60, 90, 180, 365.

Propose and seek comment on guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and manufacturer effectuation of maximum fair price under such program in 2026, 2027, and 2028 (60 days); Recommendations to stabilize and reduce Medicare Part D premiums (180 days); HHS Secretary to develop and implement a rulemaking plan and select for testing a payment model to improve the ability of the Medicare program (1 year); Secretary shall publish in Federal Register a plan to conduct a survey to determine the hospital acquisition costs for outpatient drugs (180 days); Recommendations to President regarding how to best ensure that manufacturers pay accurate Medicaid drug rebates, promote payment innovation, link payments for drugs to the value, and support state drug spending management (180 days); Secretary shall take action to ensure future grants (under 330(e) of the Public Health Service Act, as amended, 42 U.S.C. 254b(e)) are conditioned upon establishing practices to make insulin and injectable epinephrine available at discounted prices for those with qualifying low incomes (90 days); Provide recommendations to President to promote a competitive, efficient, resilient, and transparent pharmaceutical value chain (90 days); Secretary shall report recommendations to accelerate the approval of generics and biosimilars and improve OTC drug reclassification (180 days); Secretary shall take steps to streamline the Importation Program under section 804 of the Federal Food, Drug, and Cosmetic Act (90 days); Propose regulations to prevent shifts to more expensive drug administration settings (180 days); Secretary shall evaluate and propose regulations to improve employer health plan fiduciary transparency and indirect pharmacy benefit manager compensation (180 days); Secretary shall conduct join public listening sessions and issue report a with recommendations to reduce anti-competitive practices by pharmaceutical manufacturers (180 days).

No known legal challenges.